Ginkgo Bioworks Holdings Inc. Class A Common Stock (DNA)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I begin with the numbers, not the story. Ginkgo Bioworks sells cell engineering and biosecurity services, but the filed record shows a business that has not yet proven it can stand on its own. In fiscal 2025, the year ended 2025-12-31, revenue was $170.2 million and net income was -$312.8 million, or diluted EPS -$5.64. That follows fiscal 2024 revenue of $227.0 million and net loss of $547.0 million, and fiscal 2023 revenue of $251.5 million and net loss of $892.9 million. The loss has narrowed, but revenue has fallen sharply, and the most recent quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $20.2 million and net loss of $46.7 million, or diluted EPS -$0.75. The balance-sheet and cash-flow picture is not Graham-like. FairStock calculations put the shares at a P/B of 1.78 and a negative P/E of -2.21 at the 2026-10-13 close of $11.76, with ROE of -59.94% and ROCE of -16.72%. Trailing free cash flow was -$174.8 million, a FCF yield of -26.7%, while the Altman Z-Score of -8.05 and Piotroski F-Score of 4/9 signal financial stress. FairStock assigns no Peter Lynch category because the company lost money in each of the last four years. I see no durable moat demonstrated by these figures: shrinking revenue and heavy cash burn suggest the platform has not yet converted scientific promise into durable economics. The stock may be an option on a future turnaround, but as a business it currently lacks the earning power and financial strength I require. Price is not value without profits and cash.

In plain English: Ginkgo Bioworks uses cell engineering to help other companies create biological products, and it also has a biosecurity business. The business looks weak today: it has lost money for years, revenue has been falling, and it burns cash. At $11.76 on 2026-10-13, the price does not look cheap against those losses; it depends mostly on hopes for a future turnaround, not current profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer